Manage Side Effects: Some patients may experience side effects, especially when starting semaglutide
Dose increases should always be guided by a healthcare provider to minimize side effects and ensure safety
[16] [17] People who are already carnitine-deficient may feel less fatigue, but the injection should not be viewed as a stand-alone weight-loss or athletic supplement
CagriSema Research# CagriSema has comprehensive phase 3 evidence: REDEFINE 1 (obesity): Phase 3, 68 weeks, ~3,400 patients
The SMART trial Published in Nature Medicine in 2024, it tested semaglutide 2.4 mg specifically in 101 people with CKD and obesity, without diabetes
Asking the right questions helps providers identify trusted, licensed partners that prioritize patient safety, regulatory alignment, and consistent quality